Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer

被引：0

作者：

Hochmair, Maximilian ^{[1
]}

Kiiskinen, Urpo ^{[2
,3
]}

D'yachkova, Yulia ^{[4
]}

Puri, Tarun ^{[5
]}

Wang, Xuwen ^{[6
]}

Wolowacz, Sorrel ^{[7
]}

Vickers, Adrian ^{[7
]}

Nadal, Ernest ^{[8
,9
]}

机构：

[1] Klin Floridsdorf, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria

[2] Eli Lilly & Co, Indianapolis, IN USA

[3] Eli Lilly & Co, Int Value & Access, Helsinki, Finland

[4] Eli Lilly & Co, Stat, Vienna, Austria

[5] Eli Lilly & Co, Thorac Oncol Global Med Affairs, Gurgaon, Haryana, India

[6] Eli Lilly & Co, Real World Adv Anal, Indianapolis, IN USA

[7] RTI Hlth Solut, Hlth Econ, Manchester, England

[8] Inst Catala Oncol ICO, Dept Med Oncol, Avda Granvia De Lhospitalet, Lhospitalet de Llobregat 08908, Barcelona, Spain

[9] Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Preclin & Expt Res Thorac Tumors PReTT Grp, Lhospitalet de Llobregat, Barcelona, Spain

来源：

FUTURE ONCOLOGY | 2025年 / 21卷 / 15期

关键词：

NSCLC; matching-adjusted indirect comparison; RET inhibitor; selpercatinib; pralsetinib; TYROSINE KINASE INHIBITOR; PREVIOUSLY TREATED PATIENTS; 2ND-LINE TREATMENT; NSCLC PATIENTS; RETROSPECTIVE ANALYSIS; PREDICTIVE FACTORS; PROGNOSTIC-FACTORS; TREATMENT PATTERNS; CLINICAL-OUTCOMES; PLATINUM-DOUBLET;

D O I：

10.1080/14796694.2025.2508132

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AimsSelpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methodsEfficacy and safety were compared using matching-adjusted indirect comparison.ResultsMedian progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade >= 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.ConclusionOutcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade >= 3 TRAEs.

引用

页码：1867 / 1878

页数：12

共 97 条

[21]

Fialkowski A., 2018, INTERNET

[22] Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study [J].

Fujimoto, Daichi ;

Yoshioka, Hiroshige ;

Kataoka, Yuki ;

Morimoto, Takeshi ;

Kim, Young Hak ;

Tomii, Keisuke ;

Ishida, Tadashi ;

Hirabayashi, Masataka ;

Hara, Satoshi ;

Ishitoko, Manabu ;

Fukuda, Yasushi ;

Hwang, Moon Hee ;

Sakai, Naoki ;

Fukui, Motonari ;

Nakaji, Hitoshi ;

Morita, Mitsunori ;

Mio, Tadashi ;

Yasuda, Takehiro ;

Sugita, Takakazu ;

Hirai, Toyohiro .

LUNG CANCER, 2018, 119 :14-20

[23] Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study [J].

Fukui, Tomoya ;

Okuma, Yuriko ;

Nakahara, Yoshiro ;

Otani, Sakiko ;

Igawa, Satoshi ;

Katagiri, Masato ;

Mitsufuji, Hisashi ;

Kubota, Masaru ;

Hiyoshi, Yasuhiro ;

Ishihara, Mikiko ;

Kasajima, Masashi ;

Sasaki, Jiichiro ;

Naoki, Katsuhiko .

CLINICAL LUNG CANCER, 2019, 20 (03) :208-+

[24] Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study [J].

Gainor, Justin F. ;

Curigliano, Giuseppe ;

Kim, Dong-Wan ;

Lee, Dae Ho ;

Besse, Benjamin ;

Baik, Christina S. ;

Doebele, Robert C. ;

Cassier, Philippe A. ;

Lopes, Gilberto ;

Tan, Daniel S. W. ;

Garralda, Elena ;

Paz-Ares, Luis G. ;

Cho, Byoung Chul ;

Gadgeel, Shirish M. ;

Thomas, Michael ;

Liu, Stephen, V ;

Taylor, Matthew H. ;

Mansfield, Aaron S. ;

Zhu, Viola W. ;

Clifford, Corinne ;

Zhang, Hui ;

Palmer, Michael ;

Green, Jennifer ;

Turner, Christopher D. ;

Subbiah, Vivek .

LANCET ONCOLOGY, 2021, 22 (07) :959-969

[25] Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis [J].

Garassino, Marina Chiara ;

Kawaguchi, Tomoya ;

Gregorc, Vanesa ;

Rulli, Eliana ;

Ando, Masahiko ;

Marsoni, Silvia ;

Isa, Shun-Ichi ;

Novello, Silvia ;

Farina, Gabriella ;

Barni, Sandro ;

Torri, Valter ;

Cinquini, Michela .

ESMO OPEN, 2018, 3 (06)

[26]

Garde-Noguera J, 2018, CLIN TRANSL ONCOL, V20, P1072, DOI 10.1007/s12094-017-1829-5

[27] Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial [J].

Griesinger, F. ;

Curigliano, G. ;

Thomas, M. ;

Subbiah, V. ;

Baik, C. S. ;

Tan, D. S. W. ;

Lee, D. H. ;

Misch, D. ;

Garralda, E. ;

Kim, D. -W. ;

van der Wekken, A. J. ;

Gainor, J. F. ;

Paz-Ares, L. ;

Liu, S., V ;

Kalemkerian, G. P. ;

Houvras, Y. ;

Bowles, D. W. ;

Mansfield, A. S. ;

Lin, J. J. ;

Smoljanovic, V. ;

Rahman, A. ;

Kong, S. ;

Zalutskaya, A. ;

Louie-Gao, M. ;

Boral, A. L. ;

Mazieres, J. .

ANNALS OF ONCOLOGY, 2022, 33 (11) :1168-1178

[28] Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves [J].

Guyot, Patricia ;

Ades, A. E. ;

Ouwens, Mario J. N. M. ;

Welton, Nicky J. .

BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12

[29] Pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy plus /-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison [J].

Halmos, Balazs ;

Burke, Thomas ;

Kalyvas, Chrysostomos ;

Vandormael, Kristel ;

Frederickson, Andrew ;

Piperdi, Bilal .

LUNG CANCER, 2021, 155 :175-182

[30] A Matching-Adjusted Indirect Comparison of Pembrolizumab plus Chemotherapy vs. Nivolumab plus Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC [J].

Halmos, Balazs ;

Burke, Thomas ;

Kalyvas, Chrysostomos ;

Insinga, Ralph ;

Vandormael, Kristel ;

Frederickson, Andrew ;

Piperdi, Bilal .

CANCERS, 2020, 12 (12) :1-15

← 1 2 3 4 5 6 7 8 9 10 →